Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Cam Gallagher Biography and Net Worth

Director of Zentalis Pharmaceuticals

Cam Gallagher has been a member of the board of directors since our founding. Mr. Gallagher has more than 27 years of experience with a focus on corporate development, marketing and early stage company formation and financing. In addition to Zentalis, he currently serves on the board of directors of VelosBIO, Ocuphire and SelectION. He is currently Chief Business Officer of Immusoft, a private company developing gene modified cell therapies for orphan diseases. Previously, Cam was a board member and Chief Business Officer at Retrosense Therapeutics, which was acquired by Allergan in 2016. He was the Managing Director of Nerveda, LLC, a life science seed fund he co-founded in June 2007. Prior to these roles he held leadership positions at Oncternal, Zavante, Verus Pharma, CV Therapeutics and Dura Pharma. Mr. Gallagher holds an MBA from the University of San Diego and a BS in Business Administration from Ohio University.

What is Cam Gallagher's net worth?: The estimated net worth of Cam Gallagher is at least $2.20 million as of May 31st, 2024. Mr. Gallagher owns 633,680 shares of Zentalis Pharmaceuticals stock worth more than $2,198,870 as of November 16th. This net worth estimate does not reflect any other assets that Mr. Gallagher may own. Additionally, Mr. Gallagher receives a salary of $892,150.00 as Director at Zentalis Pharmaceuticals. Learn More about Cam Gallagher's net worth.
How old is Cam Gallagher?: Mr. Gallagher is currently 54 years old. There are 6 older executives and no younger executives at Zentalis Pharmaceuticals. The oldest executive at Zentalis Pharmaceuticals is Dr. Diana F. Hausman M.D., Chief Medical Officer & Director, who is 61 years old. Learn More on Cam Gallagher's age.
What is Cam Gallagher's salary?: As the Director of Zentalis Pharmaceuticals, Inc., Mr. Gallagher earns $892,150.00 per year. The highest earning executive at Zentalis Pharmaceuticals is Dr. Kimberly Lynn Blackwell M.D., CEO & Director, who commands a salary of $1,170,000.00 per year. Learn More on Cam Gallagher's salary.
How do I contact Cam Gallagher?: The corporate mailing address for Mr. Gallagher and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected]. Learn More on Cam Gallagher's contact information.
Has Cam Gallagher been buying or selling shares of Zentalis Pharmaceuticals?: Cam Gallagher has not been actively trading shares of Zentalis Pharmaceuticals within the last three months. Most recently, Cam Gallagher sold 9,597 shares of the business's stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.98, for a transaction totalling $114,972.06. Following the completion of the sale, the chief financial officer now directly owns 633,680 shares of the company's stock, valued at $7,591,486.40. Learn More on Cam Gallagher's trading history.
Who are Zentalis Pharmaceuticals' active insiders?: Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Zentalis Pharmaceuticals?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 18,302 shares worth more than $205,276.56. The most recent insider tranaction occured on October, 4th when insider Vincent Vultaggio sold 1,603 shares worth more than $5,097.54. Insiders at Zentalis Pharmaceuticals own 3.6% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.
Information on this page was last updated on 10/4/2024.

Cam Gallagher Insider Trading History at Zentalis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/31/2024	Sell	9,597	$11.98	$114,972.06	633,680
2/12/2024	Sell	1,173	$11.44	$13,419.12	643,277
5/31/2023	Sell	27,768	$26.27	$729,465.36	463,502
2/13/2023	Sell	3,332	$20.42	$68,039.44	499,771
2/6/2023	Sell	10,000	$22.27	$222,700.00	503,103
1/17/2023	Sell	10,000	$24.15	$241,500.00	352,011
1/5/2023	Sell	10,000	$21.02	$210,200.00	362,011
11/15/2022	Sell	12,500	$22.77	$284,625.00	372,011
11/7/2022	Sell	12,500	$23.67	$295,875.00	396,885
10/17/2022	Sell	12,500	$23.51	$293,875.00	409,385
10/5/2022	Sell	12,500	$22.32	$279,000.00	431,885
9/15/2022	Sell	12,500	$25.26	$315,750.00	454,385
4/5/2022	Sell	10,000	$50.48	$504,800.00	355,813
3/15/2022	Sell	10,000	$41.92	$419,200.00
3/7/2022	Sell	10,000	$44.94	$449,400.00
2/14/2022	Sell	7,188	$50.19	$360,765.72
2/7/2022	Sell	10,000	$53.45	$534,500.00
1/18/2022	Sell	10,000	$62.64	$626,400.00
1/5/2022	Sell	10,000	$75.49	$754,900.00
12/15/2021	Sell	10,000	$74.03	$740,300.00
12/6/2021	Sell	10,000	$71.33	$713,300.00
11/15/2021	Sell	10,000	$75.36	$753,600.00
11/5/2021	Sell	10,000	$82.95	$829,500.00
10/1/2021	Sell	10,000	$66.15	$661,500.00
9/1/2021	Sell	10,000	$67.52	$675,200.00	470,962
8/2/2021	Sell	10,000	$51.02	$510,200.00	483,419
7/6/2021	Sell	15,798	$46.88	$740,610.24
7/2/2021	Sell	10,000	$49.58	$495,800.00
6/1/2021	Sell	10,000	$54.06	$540,600.00	516,845
5/3/2021	Sell	10,000	$59.25	$592,500.00	534,373
1/4/2021	Sell	10,000	$51.93	$519,300.00	577,773
12/7/2020	Sell	6,692	$53.52	$358,155.84	613,471
12/4/2020	Sell	7,474	$50.98	$381,024.52	613,471
11/23/2020	Sell	10,000	$46.54	$465,400.00

Cam Gallagher Buying and Selling Activity at Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $3.47

$3.36

$4.00

50 Day Range

MA: $3.42

$2.70

$4.36

2 Week Range

Now: $3.47

$2.66

$18.07

Volume

1,832,087 shs

Average Volume

1,566,191 shs

Market Capitalization

$247.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74

War on Elon Escalates…

From Porter & Company | Ad

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

Cam Gallagher Biography and Net Worth

What is Cam Gallagher's net worth?

How old is Cam Gallagher?

What is Cam Gallagher's salary?

How do I contact Cam Gallagher?

Has Cam Gallagher been buying or selling shares of Zentalis Pharmaceuticals?

Who are Zentalis Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Zentalis Pharmaceuticals?